Skip to main content
SpringerLink
Log in

Variability in derived parameters of furosemide pharmacokinetics

  • Published:
Journal of Pharmacokinetics and Biopharmaceutics Aims and scope Submit manuscript

Abstract

The pharmacokinetics of furosemide in normal man reported from a number of investigators show great discrepancies. We have evaluated the effect on derived pharmacokinetic parameters of furosemide of using different weighting factors or fewer data points to fit the same set of data to an exponential equation, or using noncompartmental analysis. Terminal half-lives of furosemide differed vastly, as did the volume of distribution, but to a lesser extent. The plasma clearance was rather consistent with the different methods used. Thus the discrepancies of the pharmacokinetics of furosemide may, in large part, be due to different methods of analysis of the data. The terminal half-life was most subject to errors of method and the plasma clearance the least.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. F. Andreasen, H. E. Hansen, and E. Mikkelsen. Pharmacokinetics of furosemide in anephric patients and in normal subjects.Eur. J. Clin. Pharmacol. 13:41–48 (1978).

    Article  CAS  PubMed  Google Scholar 

  2. F. Andreasen and E. Mikkelsen. Distribution, elimination and effect of furosemide in normal subjects and in patients with heart failure.Eur. J. Clin. Pharmacol. 12:15–22 (1977).

    Article  CAS  PubMed  Google Scholar 

  3. B. Beermann, E. Dalén, and B. Lindstrom. Elimination of furosemide in healthy subjects and in those with renal failure.Clin. Pharmacol. Ther. 22:70–78 (1977).

    CAS  PubMed  Google Scholar 

  4. R. A. Branch, C. J. C. Roberts, M. Homeida, and D. Levine. Determinants of response to furosemide in normal subjects.Br. J. Clin. Pharmacol. 4:121–127 (1977).

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. P. Chennavasin, R. Seiwell, D. C. Brater, and W. M. M. Liang. Pharmacodynamic analysis of the furosemide-probenecid interaction in man.Kidney Int. 16:187–195 (1979).

    Article  CAS  PubMed  Google Scholar 

  6. R. E. Cutler, A. W. Forrey, T. G. Christopher, and B. M. Kimpel. Pharmacokinetics of furosemide in normal subjects and functionally anephric patients.Clin. Pharmacol. Ther. 15:588–596 (1974).

    CAS  PubMed  Google Scholar 

  7. M. Homeida, C. Roberts, and R. A. Branch. Influence of probenecid and spironolactone on furosemide kinetics and dynamics in man.Clin. Pharmacol. Ther. 22:402–409 (1977).

    CAS  PubMed  Google Scholar 

  8. J. Honari, A. Blair, and R. Cutler. Effects of probenecid on furosemide kinetics and natriuresis in man.Clin. Pharmacol. Ther. 22:395–401 (1977).

    CAS  PubMed  Google Scholar 

  9. M. R. Kelly, R. E. Cutler, A. W. Forrey, and B. M. Kimpel. Pharmacokinetics of orally administered furosemide.Clin. Pharmacol. Ther. 15:178–186 (1973).

    Google Scholar 

  10. J. R. Lawrence, A. F. Ansari, H. L. Elliott, D. J. Sumner, G. R. Brunton, and R. Whiting. Kinetic and dynamic comparison of piretanide and furosemide.Clin. Pharmacol. Ther. 23:558–565 (1978).

    CAS  PubMed  Google Scholar 

  11. A. Rane, J. P. Villeneuve, W. J. Stone, A. S. Nies, G. R. Wilkinson, and R. A. Branch. Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia.Clin. Pharmacol. Ther. 24:199–207 (1978).

    CAS  PubMed  Google Scholar 

  12. W. Rupp and P. Hajdu. Pharmacokinetics and pharmacodynamics of a diuretic agent. In H. J. Dengler (ed.),Pharmacological and Clinical Significance of Pharmacokinetics, F. K. Schutlauer Verlag, Stuttgart, 1970.

    Google Scholar 

  13. D. E. Smith, D. C. Brater, E. T. Lin, and L. Z. Benet. Attenuation of furosemide's diuretic effect by indomethacin: pharmacokinetic evaluation.J. Pharmacokinet. Biopharm. 7:265–274 (1979).

    Article  CAS  PubMed  Google Scholar 

  14. W. J. Tilstone and A. Fine. Furosemide kinetics in renal failure.Clin. Pharmacol. Ther. 23:644–650 (1978).

    CAS  PubMed  Google Scholar 

  15. L. Z. Benet. Pharmacokinetics/pharmacodynamics of furosemide in man: a review.J. Pharmacokinet. Biopharm. 7:1–27 (1979).

    Article  CAS  PubMed  Google Scholar 

  16. R. E. Cutler and A. D. Blair. Clinical pharmacokinetics of frusemide.Clin. Pharmacokinet. 4:279–296 (1979).

    Article  CAS  PubMed  Google Scholar 

  17. P. J. Fell and M. T. Stevens. Pharmacokinetics—use and abuses.Eur. J. Clin. Pharmacol. 8:241–248 (1975).

    Article  CAS  PubMed  Google Scholar 

  18. J. G. Wagner. Pharmacokinetic parameters estimated from intravenous data by uniform methods and some of their uses.J. Pharmacokinet. Biopharm. 5:161–182 (1977).

    Article  CAS  PubMed  Google Scholar 

  19. W. J. Westlake. Use of statistical methods in evaluation ofin vivo performance of dosage forms.J. Pharm. Sci. 62:1579–1589 (1973).

    Article  CAS  PubMed  Google Scholar 

  20. C. M. Metzler, G. L. Elfring, and A. J. McEwen. A package of computer programs for pharmacokinetic modeling (abstract).Biometrics 30:562 (1974).

    Article  Google Scholar 

  21. A. J. Sedman and J. G. Wagner. CSTRIP, a fortran IV computer program for obtaining initial polyexponential parameter estimates.J. Pharm. Sci. 65:1006–1010 (1976).

    Article  CAS  PubMed  Google Scholar 

  22. H. G. Boxenbaum, S. Riegelman, and R. M. Elashoff. Statistical estimations in pharmacokinetics.J. Pharmacokinet. Biopharm. 2:123–148 (1974).

    Article  CAS  PubMed  Google Scholar 

  23. P. Chennavasin, R. Seiwell, and D. C. Brater. Pharmacokinetic-dynamic analysis of the indomethacin-furosemide interaction in man.J. Pharmacol. Exp. Ther. 215:77–81 (1980).

    CAS  PubMed  Google Scholar 

  24. L. Z. Benet and R. L. Galeazzi. Noncompartmental determination of the steady-state volume of distribution.J. Pharm. Sci. 68:1071–1074 (1979).

    Article  CAS  PubMed  Google Scholar 

  25. H. I. Glass and A. C. deGarreta. The quantitative limitations of exponential curve fitting.Phys. Med. Biol. 16:119–130 (1971).

    Article  CAS  PubMed  Google Scholar 

  26. H. P. Wijnand and C. J. Timmer. Curve fitting and modeling in pharmacokinetics: all programs are equal, but some programs are more equal than others.J. Pharmacokinet. Biopharm. 7:681–684 (1979).

    Article  CAS  PubMed  Google Scholar 

  27. K. T. Muir and S. Riegelman. Curve fitting and modeling in pharmacokinetics.J. Pharmacokinet., Biopharm. 7:685–687 (1979).

    Article  CAS  Google Scholar 

  28. T. Ishizaki, M. Watanabe, and N. Morishita. The effect of assay methods of plasma levels and pharmacokinetics of theophylline: HPLC and EIA.Br. J. Clin. Pharmacol. 7:333–341 (1979).

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. R. G. Nayak, R. D. Smith, J. H. Chamberlain, A. Polk, A. F. Delong, T. Herozeg, P. B. Chemburlear, R. S. Joslin, and N. H. Reavey-Canwell. Methaqualone pharmacokinetics after single and multiple-dose administration in man.J. Pharmacokinet. Biopharm. 2:107–121 (1974).

    Article  CAS  PubMed  Google Scholar 

  30. M. Gibaldi and D. Perrier.Pharmacokinetics. Marcel Dekker, New York, 1975, pp. 307–308.

    Google Scholar 

  31. J. G. Wagner.Fundamentals of Clinical Pharmacokinetics. Drug Intelligence Publications, Hamilton, Ill., 1975, pp. 288–290.

    Google Scholar 

  32. P. V. Pedersen. Curve fitting and modeling in pharmacokinetics and some practical experiences in NONLIN and a new program FUNFIT.J. Pharmacokinet. Biopharm. 5:513–530 (1977).

    Article  CAS  PubMed  Google Scholar 

  33. C. M. Metzler and G. L. Elfring. Curve fitting and modeling in pharmacokinetics: a response.J. Pharmacokinet. Biopharm. 6:443–446 (1978).

    Article  CAS  PubMed  Google Scholar 

  34. C. C. Peck, L. Sheiner, S. Beal, and A. Nichols. Pharmacokinetic data analysis using extended least-squares nonlinear regression.Clin. Pharmacol. Ther. 27:277–278 (1980).

    Google Scholar 

Download references

Author information

Author notes

  1. Polavat Chennavasin

    Present address: Department of Medicine, Ramathibodi Hospital, Bangkok 4, Thailand

Authors and Affiliations

  1. Recipient of a training grant in Clinical Pharmacology from the National Institute of Health 5-T32-GM07247, The University of Texas Health Science Center at Dallas, 75235, Dallas, Texas

    Polavat Chennavasin

  2. Medical Computing Resources Center, The University of Texas Health Science Center at Dallas, 75235, Dallas, Texas

    Robert A. Johnson

  3. Departments of Pharmacology and Internal Medicine, The University of Texas Health Science Center at Dallas, 75235, Dallas, Texas

    D. Craig Brater

Authors
  1. Polavat Chennavasin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert A. Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Craig Brater
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This work was supported by NIH Young Investigator Award R23-H122882 and a General Clinical Research Center Grant USPHS 1-M01-RR006331.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chennavasin, P., Johnson, R.A. & Brater, D.C. Variability in derived parameters of furosemide pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics 9, 623–633 (1981). https://doi.org/10.1007/BF01061029

Download citation

  • Received:

  • Revised:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01061029

Key words

Search

Navigation